Explore
Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting, Highlighting Antitumor Efficacy
Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting, Highlighting Antitumor Efficacy
Read More
Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy
Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy
Read More
Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting
Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting
Read More
Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026
Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026
Read More
Trendline
Bristol Myers Squibb to Present New Oncology Data at ASCO 2026, Highlighting Scientific Innovations
Bristol Myers Squibb to Present New Oncology Data at ASCO 2026, Highlighting Scientific Innovations
Read More
Trendline
SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026
SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026
Read More
Trendline
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer
Read More
Trendline
Accent Therapeutics to Present Phase 1/2 Study of ATX-295 at ASCO 2026
Accent Therapeutics to Present Phase 1/2 Study of ATX-295 at ASCO 2026
Read More
Trendline
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomally Instable Tumors
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomally Instable Tumors
Read More
Trendline
Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments
Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments
Read More
Trendline
Exelixis to Present Key Findings on Cancer Treatments at ASCO 2026
Exelixis to Present Key Findings on Cancer Treatments at ASCO 2026
Read More
Trendline
Sarah Cannon Research Institute and Pfizer Collaborate to Accelerate Oncology Drug Development
Sarah Cannon Research Institute and Pfizer Collaborate to Accelerate Oncology Drug Development
Read More
